Home

Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)

249.23
0.00 (0.00%)

Alnylam Pharmaceuticals is a biopharmaceutical company focused on advancing innovative therapies using RNA interference (RNAi) technology to treat a range of genetic diseases

The company is dedicated to developing medicines that can selectively silence disease-causing genes, thereby addressing the underlying causes of conditions such as hereditary transthyretin-mediated amyloidosis and other rare disorders. With a strong commitment to research and development, Alnylam aims to deliver transformative treatments that improve patient outcomes and enhance quality of life for those affected by severe or life-threatening diseases.

SummaryNewsPress ReleasesChartHistoricalFAQ
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · March 3, 2025
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Yearsbenzinga.com
Via Benzinga · February 26, 2025
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga.com
Via Benzinga · February 18, 2025
Alnylam Delivers a Big Q4 Earnings Beatfool.com
Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.
Via The Motley Fool · February 13, 2025
Earnings Scheduled For February 13, 2025benzinga.com
Via Benzinga · February 13, 2025
Breaking Down Alnylam Pharmaceuticals: 7 Analysts Share Their Viewsbenzinga.com
Via Benzinga · February 11, 2025
Looking Into Alnylam Pharmaceuticals's Recent Short Interestbenzinga.com
Via Benzinga · February 10, 2025
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · January 30, 2025
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interestbenzinga.com
Via Benzinga · January 16, 2025
$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · January 13, 2025
What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticalsbenzinga.com
Via Benzinga · January 13, 2025
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.investors.com
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via Investor's Business Daily · January 9, 2025
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimisticbenzinga.com
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.
Via Benzinga · January 3, 2025
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Yearsbenzinga.com
Via Benzinga · January 3, 2025
How Is The Market Feeling About Alnylam Pharmaceuticals?benzinga.com
Via Benzinga · December 24, 2024
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · December 9, 2024
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (24 Ratings)benzinga.com
Via Benzinga · November 4, 2024
Alnylam Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)benzinga.com
Via Benzinga · November 12, 2024
This Airbnb Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesdaybenzinga.com
Via Benzinga · November 12, 2024
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacksbenzinga.com
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and Merck.
Via Benzinga · November 8, 2024
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interestbenzinga.com
Via Benzinga · October 31, 2024
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · October 23, 2024
Why NASDAQ:ALNY qualifies as a high growth stock.chartmill.com
Why ALNYLAM PHARMACEUTICALS INC (NASDAQALNY) qualifies as a high growth stock.
Via Chartmill · October 15, 2024
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Upinvestors.com
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
Via Investor's Business Daily · October 18, 2024
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · October 11, 2024